Market capitalization | $532.90m |
Enterprise Value | $268.77m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.29 |
P/S ratio (TTM) P/S ratio | 6.53 |
P/B ratio (TTM) P/B ratio | 1.94 |
Revenue growth (TTM) Revenue growth | 2,582.55% |
Revenue (TTM) Revenue | $81.63m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
8 Analysts have issued a Fulcrum Therapeutics Inc forecast:
8 Analysts have issued a Fulcrum Therapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 82 82 |
2,585%
2,585%
|
|
Gross Profit | 80 80 |
11,457%
11,457%
|
|
EBITDA | -31 -31 |
71%
71%
|
EBIT (Operating Income) EBIT | -33 -33 |
69%
69%
|
Net Profit | -20 -20 |
79%
79%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Alexander Sapir |
Employees | 76 |
Founded | 2015 |
Website | www.fulcrumtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.